Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
125.63
+1.09 (0.88%)
At close: Oct 23, 2026, 4:00 PM EDT
124.58
-1.05 (-0.84%)
After-hours: Oct 23, 2026, 7:30 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year. That makes Halozyme Therapeutics the 21,379th largest employer in the world and 2,807th in the United States.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$3,933,187
Profits / Employee
$977,768
Market Cap
14.26B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 1,003 |
| Madrigal Pharmaceuticals | 915 |
HALO News
- 1 day ago - Halozyme to Report Third Quarter 2026 Financial and Operating Results - PRNewsWire
- 2 days ago - Halozyme's Strong Earnings Growth Sends Shares Higher - FXEmpire
- 9 days ago - Halozyme rises 7.5% - TheFly
- 10 days ago - Halozyme price target raised to $130 from $105 at TD Cowen - TheFly
- 15 days ago - Halozyme price target raised to $130 from $115 at H.C. Wainwright - TheFly
- 15 days ago - Halozyme price target raised to $78 from $70 at JPMorgan - TheFly
- 16 days ago - Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
- 16 days ago - Halozyme announces Dutch court of the Hague found Merck infringed patents - TheFly